Mesirow Institutional Investment Management Inc. Increases Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Mesirow Institutional Investment Management Inc. grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 37.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 302,148 shares of the biopharmaceutical company's stock after buying an additional 82,643 shares during the period. Mesirow Institutional Investment Management Inc. owned approximately 0.24% of Halozyme Therapeutics worth $14,446,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. MetLife Investment Management LLC grew its holdings in Halozyme Therapeutics by 7.8% during the fourth quarter. MetLife Investment Management LLC now owns 145,265 shares of the biopharmaceutical company's stock worth $6,945,000 after buying an additional 10,538 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S grew its position in shares of Halozyme Therapeutics by 45.1% during the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 427,207 shares of the biopharmaceutical company's stock valued at $20,425,000 after acquiring an additional 132,795 shares during the period. Capital World Investors purchased a new stake in Halozyme Therapeutics in the fourth quarter worth $35,773,000. Dimensional Fund Advisors LP grew its stake in shares of Halozyme Therapeutics by 2.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company's stock worth $92,446,000 after acquiring an additional 47,795 shares during the period. Finally, Alpha DNA Investment Management LLC raised its stake in Halozyme Therapeutics by 7.4% in the 4th quarter. Alpha DNA Investment Management LLC now owns 10,109 shares of the biopharmaceutical company's stock valued at $483,000 after acquiring an additional 695 shares during the period. 97.79% of the stock is owned by institutional investors.

Insider Buying and Selling at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares of the company's stock, valued at $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the sale, the director now directly owns 38,611 shares of the company's stock, valued at approximately $2,173,799.30. This trade represents a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,200 shares of company stock valued at $1,286,568 over the last quarter. 2.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on HALO. HC Wainwright restated a "buy" rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research report on Friday. JPMorgan Chase & Co. raised their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a report on Monday. Wells Fargo & Company dropped their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Piper Sandler boosted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday, January 10th. Finally, Benchmark restated a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $62.89.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO traded up $1.29 during trading on Friday, hitting $60.54. The company had a trading volume of 449,522 shares, compared to its average volume of 1,430,254. The firm has a market capitalization of $7.48 billion, a P/E ratio of 17.61, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 12 month low of $37.97 and a 12 month high of $66.00. The stock has a 50 day simple moving average of $60.43 and a 200 day simple moving average of $55.01. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.